Lung Cancer

Prior PD-1 Blockade Did Not Appear to Affect COVID-19 Severity in Lung Cancer

By

Victoria Forster, PhD

Publish Date July 3, 2020

There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.

Decline in Lung Cancer Mortality Affects Decreases in Overall Cancer Deaths

By

Britt Gambino

Publish Date January 14, 2020

Reductions in lung cancer mortality are driving the steady decline in overall cancer deaths.

Lung Cancer Screening: Rates Remain Low and Disparities Run High

By

Tori Rodriquez, MA, LPC, AHC

Publish Date December 30, 2019

Despite resources, lung cancer screening with low-dose computed tomography remains underutilized.

COVID-19 Pandemic Has Affected Lung Cancer Treatment Plans

More than half of patients have experienced changes in their lung cancer treatment plan as a result of the COVID-19 pandemic.

How to Improve LDCT Screening Rates in Persons at High Risk for Lung Cancer

Nurses working in primary care settings are well-situated to identify and educate patients at high risk of lung cancer who are eligible to undergo LDCT screening.

Pralsetinib Approved for Metastatic RET Fusion-Positive NSCLC

The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.

Tepotinib Gets Priority Review for Metastatic NSCLC With METex14 Skipping Mutation

The FDA has granted Priority Review to tepotinib for metastatic NSCLC whose tumors have a mutation that leads to METex14 skipping.

Changes in Lung Cancer Incidence Between Black and White Young Adults

The historically higher lung cancer incidence in young Black people compared with White people has disappeared and reversed in men and women, respectively, in the United States.